ZaBeCor Pharmaceuticals
Bala Cynwyd, Pennsylvania, United States
About ZaBeCor Pharmaceuticals
ZaBeCor Pharmaceuticals, LLC, a clinical stage biotechnology company, focuses on the development of siRNA, antisense, and other molecular technologies for the treatment of asthma, allergy, and other inflammatory and infectious diseases. Its products include Excellair, an anti-inflammatory treatment of asthma, allergy, ARDS, COPD, avian flu inflammation, uveitis, cystitis, rheumatoid arthritis, and other autoimmune and inflammatory diseases; Recruitin Phagocytosis for infection based on gene therapy; Disarmin Phagocytosis for autoimmune diseases based on gene therapy; and Hematrol Steroid for low blood platelets, anemia (hemolytic), rheumatoid arthritis, systemic lupus, ulcerative colitis, Crohn’s disease, psoriasis, and other steroid responsive autoimmune disorders. The company was founded in 1992 and is based in Bala Cynwyd, Pennsylvania.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $50.0K
- Last round: Series Unknown (Apr 2009)
- Website: zabecor.com
- Phone: 610-660-7733
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/zabecor-pharmaceuticals-2565364 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.